![]() |
JOURNAL TOOLS |
Opzioni di pubblicazione |
eTOC |
Per abbonarsi |
Sottometti un articolo |
Segnala alla tua biblioteca |
ARTICLE TOOLS |
Estratti |
Permessi |
Share |


I TUOI DATI
I TUOI ORDINI
CESTINO ACQUISTI
N. prodotti: 0
Totale ordine: € 0,00
COME ORDINARE
I TUOI ABBONAMENTI
I TUOI ARTICOLI
I TUOI EBOOK
COUPON
ACCESSIBILITÀ
REVIEWS
Panminerva Medica 2008 December;50(4):295-304
Copyright © 2008 EDIZIONI MINERVA MEDICA
lingua: Inglese
Comorbidities in polycystic ovary syndrome: their relationship to insulin resistance
Bethea S. W. 1, Nestler J. E. 1, 2
1 Division of Endocrinology and Metabolism Department of Internal Medicine Medical College of Virginia Campus Virginia Commonwealth University, Richmond, VA, USA 2 Department of Obstetrics and Gynecology Medical College of Virginia Campus Virginia Commonwealth University, Richmond, VA, USA
The polycystic ovary syndrome (PCOS) affects 5-10% of women of child-bearing age, and the diagnosis carries with it associated metabolic and cardiovascular risk factors that are likely linked to insulin resistance. Consequently, women affected by PCOS are at significant risk for developing type 2 diabetes mellitus, cardiovascular disease, and obstructive sleep apnea. Aggressive screening for glucose intolerance and cardiovascular risk factors should be performed in all PCOS patients, and, when indicated by symptomatology, affected women should be screened for sleep apnea. Long-term goals of therapy should focus on prevention of these comorbidities.